Meeting
2012 ASCO Annual Meeting
Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.
Authors
Judith Balmaña
Vall d'Hebron University Hospital, Barcelona, Spain
Judith Balmaña , Nadine M. Tung , Steven J. Isakoff , Begoña Graña , Paula D. Ryan , Rezvan Rafi , Michael Tracy , Eric Winer , José Baselga , Judy Ellen Garber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT00782574
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1009)
DOI
10.1200/jco.2012.30.15_suppl.1009
Abstract #
1009
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Joseph W. Kim
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Navid Hafez
Poster
2019 ASCO Annual Meeting
Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
First Author: Manish R. Patel